Bracco Enters Cell Therapy Manufacturing with Cell Selection and Activation Technologies Bracco Imaging today announced its first expansion into the cell therapy space, driven by its expertise and newly developed applications of its long-established microbubble technology.

FDA Approves VUEWAY® (gadopiclenol) Solution for Injection, Intravenous Use, for Use in Neonates and Infants

Bracco Invests in GMP Manufacturing Facility for Cell Therapy Product Facility upgrades support clinical-grade manufacturing of Bracco’s microbubble-based cell selection and activation technology. GMP readiness expected mid-2027.

BubbleGen™ Early Access Program Developed by Bracco, BubbleGen™ microbubbles build on more than two decades of use in diagnostic imaging and offer a bead-free alternative to traditional magnetic approaches.

Bracco Imaging Earns Second Consecutive EcoVadis Platinum Medal with Record Sustainability Score Recognition reflects Bracco Imaging’s top-tier EcoVadis performance and strengthened sustainability data, governance and procurement practices.

Major Global Milestone with U.S. FDA 510(k) Clearance and Health Canada Authorization for for VueJect®, the First Dedicated Ultrasound Contrast Delivery System VueJect® strengthens Bracco's integrated CEUS ecosystem by enabling more standardized, efficient contrast administration in cardiology imaging